PALVELLA THERAPEUTICS, INC. 8-K

What Happened
Palvella Therapeutics, Inc. announced its financial results for the year ended December 31, 2025, in a press release filed on Form 8-K on March 31, 2026. The company also disclosed that it will hold an earnings call on March 31, 2026 and will use a slide presentation during the call. The press release and the slide deck are furnished as Exhibits 99.1 and 99.2 to the 8-K and are incorporated by reference. The report was signed by Matthew Korenberg, Chief Financial Officer.

Key Details

• Filing date: March 31, 2026 (Form 8-K) reporting results for the year ended December 31, 2025.
• Items reported: 2.02 (Results of operations and financial condition) and 7.01 (Regulation FD disclosure — earnings call + slides).
• Exhibits furnished: 99.1 (press release) and 99.2 (earnings call presentation).
• Report signed by Matthew Korenberg, Chief Financial Officer.

Why It Matters
This 8-K notifies investors that Palvella has released its annual financial results and will discuss them publicly on an earnings call with accompanying slides. Investors should review the press release and presentation for details on revenue, net loss/profit, cash position, and any operational updates or guidance included in the materials. Listening to the earnings call or reading the furnished exhibits will provide the specific financial figures and management commentary needed to assess the company’s recent performance and near-term outlook.